Development of a Prognostic Nomogram for Patients with Lung Adenocarcinoma in the Stages I, II, and III Based on Immune Scores

BACKGROUND: Immunotherapy has significantly changed the treatment prospects of non-small cell lung cancer (NSCLC). However, there is no report based on immune score to predict the overall survival (OS) of lung adenocarcinoma (LUAD) in the stages I, II, and III. Therefore, this study aimed to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Hui, Zhang, Jian-Fang, Li, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627271/
https://www.ncbi.nlm.nih.gov/pubmed/34849011
http://dx.doi.org/10.2147/IJGM.S337934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627271/
https://www.ncbi.nlm.nih.gov/pubmed/34849011
http://dx.doi.org/10.2147/IJGM.S337934

Ejemplares similares